I期临床-话题@MedSci

#I期临床#

570篇内容 | 7054人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1652976, encodeId=ca2816529e6b7, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=默沙东的Keytruda治疗小细胞肺癌的III期临床，未能明显改善患者的总体生存率, objectType=article, longId=185921, objectId=fcce18592178, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcce18592178, replyNumber=0, likeNumber=98, createdTime=2020-03-03, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcce18592178, moduleTitle=默沙东的Keytruda治疗小细胞肺癌的III期临床，未能明显改善患者的总体生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcce18592178)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652946, encodeId=9761165294653, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=**名患者参加勃林格殷格翰的钠通道抑制剂治疗囊性纤维化的II期临床试验, objectType=article, longId=181606, objectId=fdfc181606fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdfc181606fb, replyNumber=0, likeNumber=0, createdTime=2020-08-07, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdfc181606fb, moduleTitle=**名患者参加勃林格殷格翰的钠通道抑制剂治疗囊性纤维化的II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fdfc181606fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652933, encodeId=05e616529338b, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Strekin AG获得282万瑞士法郎的A轮融资，以完成STR001治疗突发感觉神经性听力损失的III期临床研究, objectType=article, longId=178786, objectId=cbc51e8786dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbc51e8786dd, replyNumber=0, likeNumber=83, createdTime=2020-08-19, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbc51e8786dd, moduleTitle=Strekin AG获得282万瑞士法郎的A轮融资，以完成STR001治疗突发感觉神经性听力损失的III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbc51e8786dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652916, encodeId=e27b16529168e, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=青蒿素衍生物红斑狼疮候选新药进入II期临床, objectType=article, longId=175547, objectId=fa791e55472f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa791e55472f, replyNumber=0, likeNumber=65, createdTime=2019-10-27, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa791e55472f, moduleTitle=青蒿素衍生物红斑狼疮候选新药进入II期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa791e55472f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652921, encodeId=a8c81652921e6, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=阿斯利康和MSD宣布其PARP抑制剂Lynparza治疗前列腺癌的III期临床试验成功, objectType=article, longId=177339, objectId=a5a91e73396a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5a91e73396a, replyNumber=0, likeNumber=82, createdTime=2019-12-18, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5a91e73396a, moduleTitle=阿斯利康和MSD宣布其PARP抑制剂Lynparza治疗前列腺癌的III期临床试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5a91e73396a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652938, encodeId=764a16529380c, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=辉瑞宣布其JAK1抑制剂abrocitinib治疗特应性皮炎的第二项III期临床研究成功, objectType=article, longId=180178, objectId=8f301801e8b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f301801e8b0, replyNumber=0, likeNumber=87, createdTime=2020-04-02, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f301801e8b0, moduleTitle=辉瑞宣布其JAK1抑制剂abrocitinib治疗特应性皮炎的第二项III期临床研究成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f301801e8b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652942, encodeId=4fc5165294219, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Cymerus MSCs治疗骨关节炎的II期临床试验取得新进展, objectType=article, longId=180575, objectId=9db31805e5fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9db31805e5fb, replyNumber=0, likeNumber=88, createdTime=2020-01-09, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9db31805e5fb, moduleTitle=Cymerus MSCs治疗骨关节炎的II期临床试验取得新进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9db31805e5fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652957, encodeId=3a1c165295edc, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Lancet：Resmetirom治疗非酒精性脂肪性肝炎II期临床效果显著, objectType=article, longId=182880, objectId=6912182880b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6912182880b4, replyNumber=0, likeNumber=66, createdTime=2020-01-09, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6912182880b4, moduleTitle=Lancet：Resmetirom治疗非酒精性脂肪性肝炎II期临床效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6912182880b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652910, encodeId=b2bc165291010, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=FDA批准MRT5201进行单次剂量递增的I/II期临床试验，用于鸟氨酸氨甲酰基转移酶缺乏症, objectType=article, longId=174342, objectId=3d2b1e4342ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d2b1e4342ca, replyNumber=0, likeNumber=90, createdTime=2020-06-01, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d2b1e4342ca, moduleTitle=FDA批准MRT5201进行单次剂量递增的I/II期临床试验，用于鸟氨酸氨甲酰基转移酶缺乏症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d2b1e4342ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652983, encodeId=b4d51652983b0, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=急性偏头痛的治疗：STS101在I期临床试验中表现出良好的耐受性, objectType=article, longId=186953, objectId=314a18695378, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=314a18695378, replyNumber=0, likeNumber=153, createdTime=2020-03-07, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=314a18695378, moduleTitle=急性偏头痛的治疗：STS101在I期临床试验中表现出良好的耐受性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=314a18695378)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652956, encodeId=875e165295600, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=ObsEva在令人失望的结果后，放弃了其口服催产素受体拮抗剂nolasiban用于增加体外受精妊娠率的III期临床, objectType=article, longId=182745, objectId=f0a2182e457c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0a2182e457c, replyNumber=0, likeNumber=58, createdTime=2019-11-15, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0a2182e457c, moduleTitle=ObsEva在令人失望的结果后，放弃了其口服催产素受体拮抗剂nolasiban用于增加体外受精妊娠率的III期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0a2182e457c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652913, encodeId=a3401652913a8, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=ESMO世界胃肠癌大会：murlentamab的II期临床研究结果, objectType=article, longId=174985, objectId=0a901e49851b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a901e49851b, replyNumber=0, likeNumber=53, createdTime=2020-01-11, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a901e49851b, moduleTitle=ESMO世界胃肠癌大会：murlentamab的II期临床研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a901e49851b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652899, encodeId=077c165289993, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=BioMarin的血友病基因疗法III期临床达到终点，但其长期效应引起质疑, objectType=article, longId=167518, objectId=665116e51869, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=665116e51869, replyNumber=0, likeNumber=60, createdTime=2020-03-06, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=665116e51869, moduleTitle=BioMarin的血友病基因疗法III期临床达到终点，但其长期效应引起质疑, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=665116e51869)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652987, encodeId=d408165298e0b, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=用细菌抗击细菌！微生物群药物RBX2660已完成III期临床试验的注册, objectType=article, longId=187585, objectId=d55418e58511, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d55418e58511, replyNumber=0, likeNumber=39, createdTime=2020-11-13, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d55418e58511, moduleTitle=用细菌抗击细菌！微生物群药物RBX2660已完成III期临床试验的注册, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d55418e58511)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652978, encodeId=677a16529e80e, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=NEJM的：诺华的IgE单抗Ligelizumab在慢性自发性荨麻疹的III期临床中完胜奥马珠单抗, objectType=article, longId=186027, objectId=868418602e8e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=868418602e8e, replyNumber=0, likeNumber=63, createdTime=2020-03-13, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=868418602e8e, moduleTitle=NEJM的：诺华的IgE单抗Ligelizumab在慢性自发性荨麻疹的III期临床中完胜奥马珠单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=868418602e8e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652953, encodeId=92931652953bc, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=维昇药业宣布其TransCon人生长激素，在中国未经修饰的长效人生长激素即将在国内开展III期临床研究, objectType=article, longId=182069, objectId=fe64182069a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe64182069a8, replyNumber=0, likeNumber=93, createdTime=2019-11-16, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe64182069a8, moduleTitle=维昇药业宣布其TransCon人生长激素，在中国未经修饰的长效人生长激素即将在国内开展III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe64182069a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652958, encodeId=1cc41652958ad, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=2019年美国心脏协会科学会议：Rilonacept治疗复发性心包炎的II期临床数据, objectType=article, longId=183160, objectId=386c183160e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=386c183160e6, replyNumber=0, likeNumber=77, createdTime=2020-10-19, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=386c183160e6, moduleTitle=2019年美国心脏协会科学会议：Rilonacept治疗复发性心包炎的II期临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=386c183160e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652905, encodeId=31d51652905f8, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=第24届EHA大会：5F9联合利妥昔单抗治疗复发难治性非霍奇金淋巴瘤的Ib / II期临床试验, objectType=article, longId=168728, objectId=5792168e289d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5792168e289d, replyNumber=0, likeNumber=78, createdTime=2019-12-08, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5792168e289d, moduleTitle=第24届EHA大会：5F9联合利妥昔单抗治疗复发难治性非霍奇金淋巴瘤的Ib / II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5792168e289d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652994, encodeId=9706165299407, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=NEJM：nemolizumab治疗中重度结节性瘙痒的II期临床取得积极结果, objectType=article, longId=188515, objectId=c1f8188515d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1f8188515d5, replyNumber=0, likeNumber=0, createdTime=2020-07-04, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1f8188515d5, moduleTitle=NEJM：nemolizumab治疗中重度结节性瘙痒的II期临床取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1f8188515d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652949, encodeId=696916529499a, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=BMS的PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗非小细胞肺癌中III期临床成功, objectType=article, longId=181829, objectId=2a12181829fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a12181829fb, replyNumber=0, likeNumber=67, createdTime=2020-10-06, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a12181829fb, moduleTitle=BMS的PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗非小细胞肺癌中III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a12181829fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

I期临床

2020-05-29

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

默沙东的Keytruda治疗小细胞肺癌的III期临床，未能明显改善患者的总体生存率

2020-03-03

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

**名患者参加勃林格殷格翰的钠通道抑制剂治疗囊性纤维化的II期临床试验

2020-08-07

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Strekin AG获得282万瑞士法郎的A轮融资，以完成STR001治疗突发感觉神经性听力损失的III期临床研究

2020-08-19

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

青蒿素衍生物红斑狼疮候选新药进入II期临床

2019-10-27

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

阿斯利康和MSD宣布其PARP抑制剂Lynparza治疗前列腺癌的III期临床试验成功

2019-12-18

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

辉瑞宣布其JAK1抑制剂abrocitinib治疗特应性皮炎的第二项III期临床研究成功

2020-04-02

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Cymerus MSCs治疗骨关节炎的II期临床试验取得新进展

2020-01-09

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Lancet：Resmetirom治疗非酒精性脂肪性肝炎II期临床效果显著

2020-01-09

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

FDA批准MRT5201进行单次剂量递增的I/II期临床试验，用于鸟氨酸氨甲酰基转移酶缺乏症

2020-06-01

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

急性偏头痛的治疗：STS101在I期临床试验中表现出良好的耐受性

2020-03-07

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

ObsEva在令人失望的结果后，放弃了其口服催产素受体拮抗剂nolasiban用于增加体外受精妊娠率的III期临床

2019-11-15

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

ESMO世界胃肠癌大会：murlentamab的II期临床研究结果

2020-01-11

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

BioMarin的血友病基因疗法III期临床达到终点，但其长期效应引起质疑

2020-03-06

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

用细菌抗击细菌！微生物群药物RBX2660已完成III期临床试验的注册

2020-11-13

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

NEJM的：诺华的IgE单抗Ligelizumab在慢性自发性荨麻疹的III期临床中完胜奥马珠单抗

2020-03-13

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

维昇药业宣布其TransCon人生长激素，在中国未经修饰的长效人生长激素即将在国内开展III期临床研究

2019-11-16

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

2019年美国心脏协会科学会议：Rilonacept治疗复发性心包炎的II期临床数据

2020-10-19

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

第24届EHA大会：5F9联合利妥昔单抗治疗复发难治性非霍奇金淋巴瘤的Ib / II期临床试验

2019-12-08

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

NEJM：nemolizumab治疗中重度结节性瘙痒的II期临床取得积极结果

2020-07-04

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

BMS的PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗非小细胞肺癌中III期临床成功

2020-10-06

科室
- - 订阅+
  - 更多科室
工具
服务